Association Between C1q/TNF-Related Protein-1 Levels in Human Plasma and Epicardial Adipose Tissues and Congestive Heart Failure

Yang, Ying; Liu, Si; Zhang, Rong-Yi; Luo, Hongyu; Chen, Ling; He, Weimer; Liu, Rong; Liu, Murong; Hu, Houxiang; Chen, Mao

doi:10.1159/000479915

Cited by 31 publications

(25 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, CTRP1 forms an oligo‐heterotrimer with CTRP6, and is known to enhance glucose uptake and insulin sensitivity . Elevated levels of CTRP1 have been associated with BMI, T2DM, nonalcoholic fatty liver disease (NAFLD), congestive heart failure (CHF), and chronic kidney disease progression . CTRP3, also known as cartonectin, regulates glucose homeostasis and exhibits anti‐inflammatory immunomodulatory role .…”

Section: Discussionmentioning

confidence: 99%

Circulating levels of C1q/TNF‐α‐related protein 6 (CTRP6) in polycystic ovary syndrome

et al. 2020

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting females of reproductive age. It has been associated with cardiometabolic disorders including diabetes mellitus and cardiovascular disorders, and increases the risk of developing fecundity pathologies including recurrent pregnancy loss (RPL) and infertility. C1q/tumor necrosis factor‐α‐related protein‐6 (CTRP6) is a novel adipokine involved in glucose and lipid metabolism, host inflammation, and organogenesis. In the present study, we aimed to determine the association of serum CTRP6 levels with some components of metabolic syndrome in PCOS patients (infertile PCOS [inf‐PCOS] and PCOS‐RPL). This case–control study included 120 PCOS patients (60 inf‐PCOS and 60 PCOS‐RPL) and 60 healthy controls. Serum high‐sensitivity C‐reactive protein (hs‐CRP) and homocysteine were measured using commercial kits, while adiponectin and CTRP6 levels were assessed using ELISA technique. Inf‐PCOS and PCOS‐RPL individuals had higher levels of serum CTRP6 than controls (546.15 ± 125.02 ng/ml and 534.04 ± 144.19 ng/ml vs. 440.16 ± 159.24 ng/ml; both p < .001). Moreover, serum adiponectin levels were significantly reduced, while fasting insulin, homeostasis model assessment of insulin resistance, free testosterone, and hs‐CRP levels were significantly elevated in PCOS group, when compared with controls. Furthermore, serum CTRP6 positively associated with body mass index in all subjects. It showed an inverse correlation with adiponectin in PCOS group and subgroups. However, it had a direct association with hs‐CRP in PCOS group and inf‐PCOS subgroup, but not PCOS‐RPL subgroup. These findings unravel a probable role of CTRP6 in PCOS pathogenesis, which poses a possibility to be a good diagnostic target. However, further investigation is needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating levels of C1q/TNF‐α‐related protein 6 (CTRP6) in polycystic ovary syndrome

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In recent years, there have been many studies investigating serum levels of CTRP1 and coronary artery disease. Studies have shown that CTRP1 is a marker of human atherosclerosis and promotes atherosclerosis in [17][18][19] . The serum of the three-vessel disease had a high concentration of CTRP1 than the single-vessel disease, which was consistent with our findings.…”

Section: Discussionmentioning

confidence: 99%

Implications of C1q/TNF-related protein superfamily in patients with coronary artery disease

Zhang

Liu

et al. 2020

Sci Rep

View full text Add to dashboard Cite

The C1q complement/TNF-related protein superfamily (CTRPs) displays differential effects on the regulation of metabolic homeostasis, governing cardiovascular function. However, whether and how they may serve as predictor/pro-diagnosis factors for assessing the risks of coronary artery disease (CAD) remains controversial. Therefore, we performed a clinical study to elaborate on the implication of CTRPs (CTRP1, CTRP5, CTRP7, and CTRP15) in CAD. CTRP1 were significantly increased, whereas CTRP7 and CTRP15 levels were decreased in CAD patients compared to the non-CAD group. Significant differences in CTRP1 levels were discovered between the single-and triple-vascular-vessel lesion groups. ROC analysis revealed that CTRP7 and CTRP15 may serve as CAD markers, while CTRP1 may serve as a marker for the single-vessel lesion of CAD. CTRP1 and CTRP5 can serve as markers for the triple-vessel lesion. CTRP1 may serve as an independent risk predictor for triple-vessel lesion, whereas CTRP15 alteration may serve for a single-vessel lesion of CAD. CTRP1 may serve as a novel superior biomarker for diagnosis of severity of vessel-lesion of CAD patients. CTRP7, CTRP15 may serve as more suitable biomarker for the diagnosis of CAD patients, whereas CTRP5 may serve as an independent predictor for CAD. These findings suggest CTRPs may be the superior predictive factors for the vascular lesion of CAD and represent novel therapeutic targets against CAD. Coronary artery disease (CAD) is one of the major cardiovascular diseases, which has a serious impact on human health 1. CAD is a group of diseases including myocardial infarction, sudden angina pectoris, unstable angina pectoris, myocardial infarction, and sudden coronary death 2. Multiple risk factors for CAD have been identified, which are highly associated with metabolism influencer/regulators including obesity, hypertension, dyslipidemia, diabetes, smoking, gender, age, etc. 3. However, the sensitivity of the indicators limits the prediction and prognosis of CAD. Identification of new marker or indicator is in great need. Previous studies suggest that adipokines, well-defined adipocyte endocrine factors, are important determinants for cardiovascular disorders with or without diabetes. Previous investigations implicate adiponectin (APN)'s circulationary level is negatively associated with patients who suffered coronary artery disease and 4. CTRP (C1q complement/TNF-related protein) as a newly discovered family have shown diversity and wide distribution. Some of CTRP family members have similar metabolic effects with that of adiponectin, whereas others exert opposite effect as that adiponectin. Although emerging evidence suggests that CTRPs may serve as indicators for metabolic disorders, whether and how CTRPs may display its own unique potential relationship in predicting disease, especially cardiovascular disorders, is largely under-investigated. CTRP family contains 15 family members (CTRP1 to CTRP15). Their functions display the differences and are highly related to their distribut...

show abstract

“…It is primarily expressed and secreted by the stromal-vascular cells and visceral adipose tissue and marginally by the zona glomerulosa of the adrenal cortex and vascular wall tissue [9]. Plasma CTRP1 levels exhibited in humans significant association with body mass index (BMI) [10], type 2 DM [11] and congestive heart failure [12] and is thought to play a role in several metabolic pathways. As CTRP1 enhances glucose uptake and insulin sensitivity [13], it has been proposed as a negative feedback regulator in DM.…”

Section: Introductionmentioning

confidence: 99%

Obesity and chronic kidney disease progression—the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1

Barbieri

Goicoechea

Sánchez-Niño

et al. 2018

Clinical Kidney Journal

View full text Add to dashboard Cite

Background Obesity is a risk factor for incident chronic kidney disease (CKD) in the general population. C1q/tumour necrosis factor-related protein 1 (CTRP1) is a new adipokine with multiple vascular and metabolic effects and may modulate the association between obesity and vascular diseases. The aim of the study is to explore potential links between obesity, CTRP1 levels and CKD progression. Methods Patients with Stages 3 and 4 CKD without previous cardiovascular events were enrolled and divided into two groups according to body mass index (BMI). Demographic, clinical and analytical data and CTRP1 levels were collected at baseline. During follow-up, renal events [defined as dialysis initiation, serum creatinine doubling or a 50% decrease in estimated glomerular filtration rate (Modification of Diet in Renal Disease)] were registered. Results A total of 71 patients with CKD were divided into two groups: 25 obese (BMI >30 kg/m 2 ) and 46 non-obese. CTRP1 in plasma at baseline was higher in obese patients [median (interquartile range) 360 (148) versus 288 (188) ng/mL, P = 0.041]. No significant association was found between CTRP1 levels and CKD stage, presence of diabetes, aldosterone and renin levels, or blood pressure. Obese patients had higher systolic blood pressure (P = 0.018) and higher high-sensitivity C-reactive protein (P = 0.019) and uric acid (P = 0.003) levels, without significant differences in the percentage of diabetic patients or albuminuria. During a mean follow-up of 65 months, 14 patients had a renal event. Patients with CTRP1 in the lowest tertile had more renal events, both in the overall sample (log rank: 5.810, P = 0.016) and among obese patients (log rank: 5.405, P = 0.020). Higher CTRP1 levels were associated with slower renal progression (hazard ratio 0.992, 95% confidence interval 0.986–0.998; P = 0.001) in a model adjusted for obesity, aspirin, albuminuria and renal function. Conclusions CTRP1 levels are higher in obese than in non-obese patients with CKD. High CTRP1 levels may have a renal protective role since they were associated with slower kidney disease progression. Interventional studies are needed to explore this hypothesis.

show abstract

Association Between C1q/TNF-Related Protein-1 Levels in Human Plasma and Epicardial Adipose Tissues and Congestive Heart Failure

Cited by 31 publications

References 27 publications

Circulating levels of C1q/TNF‐α‐related protein 6 (CTRP6) in polycystic ovary syndrome

Circulating levels of C1q/TNF‐α‐related protein 6 (CTRP6) in polycystic ovary syndrome

Implications of C1q/TNF-related protein superfamily in patients with coronary artery disease

Obesity and chronic kidney disease progression—the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1

Contact Info

Product

Resources

About